Menu
Amprion’s mission: To revolutionize brain disease diagnosis. Through molecular testing, we aim to accelerate precision medicine for neurodegenerative disorders.
As a pioneer in Prion Detection Science®, we believe precision medicine is the new frontier. We strive to positively impact brain disease diagnosis and treatment as the world population ages rapidly. See our evolving scientific journey below.
2007
Neuroscientist Claudio Soto teams up with molecular pathologist Dr. Russ Lebovitz to work on detecting prions, aka misfolded proteins, relating to Creutzfeldt-Jakob Disease (CJD).
2010
As mad cow disease dissipates, the team pivots, asking: Is there a parallel between misfolded proteins in mad cow disease and human brain disorders?
2013
Dr. Soto proves there is a similarity and develops an assay to detect misfolded Abeta, a biomarker found in most Alzheimer’s patients.
2014
The team expands research to detect other misfolded proteins, including Synuclein and Tau.
2015
Revolutionize molecular testing to help doctors diagnose brain diseases accurately.
2017
Amprion expands its lab, conducting further scientific research using its proprietary Prion Detection Science®.
2018
The company establishes a state-of-the-art clinical lab run by dedicated scientists and experts, not to mention tireless bots when humans are off the clock.
2019
The US FDA awards Amprion Breakthrough Device Designation for detecting misfolded Synuclein, a key brain disease biomarker.
Feb 2020
2020
Team Amprion, standing 6-feet apart, worked through Covid and reached a significant milestone. We achieved CLIA approval for our clinical lab.
2021
Our first biomarker test helps doctors diagnose Parkinson’s, and Lewy Body Dementia by detecting misfolded Synuclein in CSF. This test is developed and validated by a licensed physician pathologist in our CAP-accredited clinical laboratory.
A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.
